Activity of the beta-lactamase inhibitor BRL 42715 against cephalosporinases produced by Enterobacteriaceae.
BRL 42715, a novel beta-lactamase inhibitor, was evaluated for its capacity to inhibit cephalosporinases. BRL 42715 was effective in potentiating the activity of antibiotics against clinical isolates of Enterobacteriaceae that produced high levels of cephalosporinases. This correlated well with the very low 50% inhibition values (< 0.004 mg/L) of BRL 42715 for cephalosporinases extracted from different species. When compared in vitro to clavulanic acid, sulbactam, and tazobactam, BRL 42715 was the most efficient inhibitor of cephalosporinase.
Laboratoire de Microbiologie Médicale, Université Paris VI, France.
X Y
XY
Zhou
M D
MD
Kitzis
J F
JF
Acar
L
L
Gutmann
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002463:Cell Membrane Permeability / Q000502:physiology; D002510:Cephalosporinase / Q000096:biosynthesis; D004357:Drug Synergism; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D007769:Lactams; D008826:Microbial Sensitivity Tests; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; C061593:C6-(N1-methyl-1,2,3-trazolylmethylene)penem; D002510:Cephalosporinase